Upadacitinib 1310726-60-3

99% up by HPLC

Product categories

New Products

Product Details

Product Information

Product name	Upadacitinib
CAS No.	1310726-60-3
Molecular Formula	C₁₇H₁₉F₃N₆O
Molecular Weight	380.3675696
Quality Standard	99% up by HPLC
Appearance	White to light brown powder

COA of Upadacitinib

ITEMS	SPECIFICATION	RESULT
Appearance	White to light brown powder	Off-white powder
Water	1.8%-2.8%	0.50%
Residue on ignition	NMT 0.10%	0.03%
Heavy metal	NMT 10 ppm	Conforms
PSD	D90 NMT 50μm	13μm
Residual solvents	Alcohol: NMT 0.50%	0.014%
	2-Methyltetrahydrofuran: NMT 0.50%	Not detected
	Heptane: NMT 0.50%	0.0087%
	Ethyl acetate: NMT 0.50%	0.33%
Related substances	The individual impurity : NMT 0.5%	0.06%
Related substances	Total impurity: NMT 1.0%	0.07%
Enantiomer	NMT 0.15%	0.05%
Purity	NLT 99.0%	99.98%
Conclusion	The products complies with the enterprise standard

Usage

Function of Upadacitinib

Upadatinib is primarily indicated for patients with refractory, moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older who have not responded well to or are unsuitable for other systemic therapies (such as hormones or biologics). The launch of upadatinib extended-release tablets provides more options for the treatment of patients with atopic dermatitis. Upatinib works by blocking the activity of Janus kinases in the JAK-STAT signaling pathway. Proinflammatory cytokine stimulation causes inflammation in rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. The JAK-STAT signaling pathway is an intracellular pathway that plays a major role in the release of pro-inflammatory cytokines.

*Products under the patent are only for R&D use